Skip to main content
Erschienen in:

17.06.2022 | Case report

Cystic degeneration during neo-adjuvant chemotherapy predicts squamous metaplasia of triple negative breast cancer: report of two cases

verfasst von: Masayuki Inoue, Ayako Kimura, Tomomi Oka, Aya Yajima, Yudai Higuchi, Tatsuki Endo, Hideki Watanabe, Hiroshi Nakagomi, Toshio Oyama

Erschienen in: International Cancer Conference Journal | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Neo-adjuvant chemotherapy (NAC) has become a standard treatment for advanced breast cancer because of the advantage of monitoring drug sensitivity and enabling breast-conserving therapy. The changes during NAC are also important to know the biological characteristics of the tumor. We experienced two cases with cystic degeneration and enhancement of the cyst wall during NAC for triple negative breast cancer (TNBC). They were diagnosed to have breast cancer with squamous metaplasia. In case 1, a 37-year-old woman with right breast cancer diagnosed as TNBC, T3N3M0, Stage 3b was treated with NAC. MRI showed a cystic degeneration with a diameter of 3.5 cm and enhancement of the cyst wall, and the other nodules were extinguished. The histopathological finding of the surgical specimen revealed solid tubular carcinoma with squamous metaplasia. In case 2, a 58-year-old woman with right breast cancer diagnosed as HER2 enriched subtype, T2N0M0 stage 2 was treated with NAC containing trastuzumab. The post-NAC MRI showed extinguishment of the mass in the right breast, but showed a cystic lesion with 24 mm in diameter and enhancement of its wall in the left breast. She underwent breast conserving surgery for bilateral breast cancer, and histopathological finding of the surgical specimen indicated complete remission of right breast cancer and squamous cell carcinoma developed in the left breast. These changes are impressive and remind us that there are metaplastic changes (especially for squamous metaplasia) with resistance to chemotherapy.
Literatur
1.
Zurück zum Zitat Mieog JS, van der Hage JA, van de Velde CJ (2007) Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev 2:CD005002 Mieog JS, van der Hage JA, van de Velde CJ (2007) Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev 2:CD005002
2.
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative Group (2018) Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol 19:27–39CrossRef Early Breast Cancer Trialists’ Collaborative Group (2018) Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol 19:27–39CrossRef
3.
Zurück zum Zitat Kumaki N, Umemura S, Tang X et al (2011) Alteration of immunohistochemical biomarkers between pre- and post-chemotherapy: hormone receptors, HER2 and Ki-67. Breast Cancer 18:98–102CrossRef Kumaki N, Umemura S, Tang X et al (2011) Alteration of immunohistochemical biomarkers between pre- and post-chemotherapy: hormone receptors, HER2 and Ki-67. Breast Cancer 18:98–102CrossRef
4.
Zurück zum Zitat Fangberget A, Nilsen LB, Hole KH et al (2010) Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging. Eur Radiol 21:1188–1199CrossRef Fangberget A, Nilsen LB, Hole KH et al (2010) Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging. Eur Radiol 21:1188–1199CrossRef
5.
Zurück zum Zitat Arlinghaus LR, Li X, Levy M et al (2010) Current and future trends in magnetic resonance imaging assessments of the response of breast tumors to neoadjuvant chemotherapy. J Oncol 2010:919620CrossRef Arlinghaus LR, Li X, Levy M et al (2010) Current and future trends in magnetic resonance imaging assessments of the response of breast tumors to neoadjuvant chemotherapy. J Oncol 2010:919620CrossRef
6.
Zurück zum Zitat Tavassoli FA (1992) Classification of metaplastic carcinomas of the breast. Pathol Annu 27(Pt 2):89–119PubMed Tavassoli FA (1992) Classification of metaplastic carcinomas of the breast. Pathol Annu 27(Pt 2):89–119PubMed
7.
Zurück zum Zitat Pezzi CM, Patel-Parekh L, Cole K et al (2007) Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base. Ann Surg Oncol 14:166–173CrossRef Pezzi CM, Patel-Parekh L, Cole K et al (2007) Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base. Ann Surg Oncol 14:166–173CrossRef
8.
Zurück zum Zitat Behranwala KA, Nasiri N, Abdullah N et al (2003) Squamous cell carcinoma of the breast: clinico-pathologic implications and outcome. Eur J Surg Oncol 29:386–389CrossRef Behranwala KA, Nasiri N, Abdullah N et al (2003) Squamous cell carcinoma of the breast: clinico-pathologic implications and outcome. Eur J Surg Oncol 29:386–389CrossRef
9.
Zurück zum Zitat Zhu J, Li K, Dong X et al (2018) Metaplastic breast carcinoma composed of epithelial-myoepithelial carcinoma and squamous cell carcinoma: a case report. Medicine (Baltimore) 97:e0364CrossRef Zhu J, Li K, Dong X et al (2018) Metaplastic breast carcinoma composed of epithelial-myoepithelial carcinoma and squamous cell carcinoma: a case report. Medicine (Baltimore) 97:e0364CrossRef
10.
Zurück zum Zitat Goldberg MT, Llaneras J, Willson TD et al (2021) Squamous cell carcinoma arising in breast implant capsules. Ann Plast Surg 86:268–272CrossRef Goldberg MT, Llaneras J, Willson TD et al (2021) Squamous cell carcinoma arising in breast implant capsules. Ann Plast Surg 86:268–272CrossRef
11.
Zurück zum Zitat Rosen PP (1997) Squamous carcinoma. Rosen’s breast pathology, 2nd edn. Lippincott Williams Wilkins, Philadelphia, pp 455–461 Rosen PP (1997) Squamous carcinoma. Rosen’s breast pathology, 2nd edn. Lippincott Williams Wilkins, Philadelphia, pp 455–461
12.
Zurück zum Zitat Wong W, Brogi E, Reis-Filho JS et al (2021) Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma. NPJ Breast Cancer 7:96CrossRef Wong W, Brogi E, Reis-Filho JS et al (2021) Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma. NPJ Breast Cancer 7:96CrossRef
13.
Zurück zum Zitat Vythianathan M, Fox P, Rhodes G et al (2019) Primary squamous carcinoma of breast—a rare entity: report of two cases and review of the literature. Pathology 51:529–531CrossRef Vythianathan M, Fox P, Rhodes G et al (2019) Primary squamous carcinoma of breast—a rare entity: report of two cases and review of the literature. Pathology 51:529–531CrossRef
14.
Zurück zum Zitat Lehmann BD, Bauer JA, Chen X et al (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig 121:2750–2767CrossRef Lehmann BD, Bauer JA, Chen X et al (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig 121:2750–2767CrossRef
15.
Zurück zum Zitat Abdelhafez AH, Musall BC, Adrada BE et al (2021) Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC). Breast Cancer Res Treat 185:1–12CrossRef Abdelhafez AH, Musall BC, Adrada BE et al (2021) Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC). Breast Cancer Res Treat 185:1–12CrossRef
16.
Zurück zum Zitat Youk JH, Son EJ, Chung J et al (2012) Triple-negative invasive breast cancer on dynamic contrast-enhanced and diffusion-weighted MR imaging: comparison with other breast cancer subtypes. Eur Radiol 22:1724–1734CrossRef Youk JH, Son EJ, Chung J et al (2012) Triple-negative invasive breast cancer on dynamic contrast-enhanced and diffusion-weighted MR imaging: comparison with other breast cancer subtypes. Eur Radiol 22:1724–1734CrossRef
Metadaten
Titel
Cystic degeneration during neo-adjuvant chemotherapy predicts squamous metaplasia of triple negative breast cancer: report of two cases
verfasst von
Masayuki Inoue
Ayako Kimura
Tomomi Oka
Aya Yajima
Yudai Higuchi
Tatsuki Endo
Hideki Watanabe
Hiroshi Nakagomi
Toshio Oyama
Publikationsdatum
17.06.2022
Verlag
Springer Nature Singapore
Erschienen in
International Cancer Conference Journal / Ausgabe 4/2022
Elektronische ISSN: 2192-3183
DOI
https://doi.org/10.1007/s13691-022-00553-y

Neu im Fachgebiet Onkologie

Studie zur HIFU bei Prostatakrebs lässt viele Fragen offen

Führt eine HIFU-Ablation beim Prostatakarzinom im Vergleich mit einer radikalen Prostatektomie zu ähnlichen onkologischen, aber besseren funktionalen Ergebnissen? Interimsdaten der französischen HIFI-Studie sind uneindeutig. In einem Kommentar zur Studie werden zumindest drei allgemeine Erkenntnisse herausgearbeitet.

Adipositas als negativer Prognosefaktor bei Kindern mit Krebs

Eine kanadische Studie weist darauf hin, dass Übergewicht zum Zeitpunkt der Krebsdiagnose ein unabhängiger Risikofaktor für schlechtere Überlebenschancen bei erkrankten Kindern und Jugendlichen sein könnte. Allerdings sind nicht alle Patientinnen und Patienten gleichermaßen betroffen.


Polypen bei nahen Verwandten – erhöhtes Darmkrebsrisiko

Werden bei erstgradigen Verwandten gutartige Darmpolypen identifiziert, ist das Risiko, selbst an einem Kolorektalkarzinom zu erkranken, deutlich erhöht – vor allem das für eine früh beginnende Erkrankung. Hier könnte sich eine frühe Koloskopie besonders lohnen.

KI-gestütztes Mammografiescreening überzeugt im Praxistest

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.